Blog

Generics and Loss of Exclusivity: Planning for Market Dynamics After Patent Expiry

Loss of exclusivity is predictable, yet many portfolios treat it as a surprise. Understanding how generic entry plays out in a given market is the[…]

Preparing for a Price Negotiation: Evidence, Fallbacks and Reference-Price Consequences

A price negotiation is won or lost on preparation. By the time you are in the room, the important decisions about what you can offer,[…]

Cost-Effectiveness and Budget Impact Models: Building for Scrutiny, Not Just Submission

An economic model is an argument expressed in numbers. Payers rarely reject the arithmetic; they reject the assumptions, and the assumptions they cannot see are[…]

QALYs and Utilities: What Payers Mean by Value and Where the Numbers Come From

The quality-adjusted life year looks simple: time lived, weighted by the quality of that time. In practice, the utility values behind it are among the[…]

Choosing Comparators for HTA: Why the Right Standard of Care Differs by Country

The comparator is the most consequential choice in a value dossier. A strong result against the wrong comparator is, to a payer, no result at[…]

Building a Payer Value Dossier: Structure, Evidence and Local Adaptation

A payer value dossier is not a regulatory dossier with a different cover. It answers a different question: not whether the medicine is safe and[…]

Patient-Relevant Outcomes and PROs: Making Quality of Life Count in HTA

Assessors increasingly ask whether a trial measured what matters to patients. Patient-reported outcomes can strengthen a reimbursement case, but only if they were planned, validated[…]

Cost-Effectiveness Thresholds in Europe: Why There Is No Single Answer

Companies often ask what cost per QALY will be accepted in Europe. The honest answer is that there is no single figure, and the better[…]

Paying for One-Off Therapies: Annuities, Outcomes-Based Deals and Practical Limits

A single treatment with lasting benefit creates a problem that conventional budgets are not built to solve: a large cost paid today for benefit that[…]

Digital Health Reimbursement in Europe: Lessons from the German DiGA Model

Reimbursing software is not the same as reimbursing a medicine or a device. Germany’s DiGA pathway remains the clearest European example of a dedicated route,[…]

1 … 14 15 16 17 18 … 34